CD8A and neoplasm: Specifically, tissues from patients with mRCC exhibited increased intra-tumoral CD8+ T-cells after combination treatment with bevacizumab and atezolizumab, a PDL1 inhibitor [129], while co-administration of axitinib plus pembrolizumab or avelumab, showed promising anti-tumor activity in patients with treatment-naive advanced RCC in phase I trials [202,203].